The PhysioMimix™ OOC Range of Single and Multi-organ Microphysiological Systems (MPS) by CN Bio by CN Bio

Why Organ-on-a-chip?  

After years of costly research and development, many drug discovery programs fail because 2D cell culture and animal models inadequately predict human responses. To mitigate the risk of late-stage failures in the clinic, researchers are increasingly adopting OOC technology to predict drug efficacy, toxicity, and pharmacokinetic profiles early in programs. Insights generated using OOC are being used to complement data derived using traditional methods, confirm discoveries, overcome inter-species differences, and bridge knowledge gaps. However, in certain scenarios, such as the development of new human-specific modalities, OOC offers a novel opportunity to validate a target hypothesis, test safety and efficacy where animal models may be altogether unsuitable due to differences in gene sequence or immunological response.   

How does the PhysioMimix OOC MPS system complement existing approaches?  

PhysioMimix™ OOC Systems facilitate the formation of 3D microtissues, or miniature organs, that behave and respond to drugs in the same way as a human by culturing multiple human cell types in a physiologically relevant environment. They maintain the phenotype and biological activity of cultures over weeks by mimicking blood flow around the human body, exposing cells to vital biomechanical stimuli, oxygen and nutrients.  

PhysioMimix microphysiological systems are available in three versions, Single-organ, Single-organ higher throughput (HT), or Multi-organ. The Single-Organ System enables detailed individual organ function and disease state modelling studies. It is compatible with Multi-chip Liver-12 plates (MPS-LC12) to generate in vitro 3D liver microtissues and the Multi-chip Barrier plate (MPS-T12) to develop barrier models (such as gut or lung) on Transwell® inserts. 

The next-generation PhysioMimix Single-organ HT System is additionally compatible with the Multi-chip Liver-48 plate, which enables higher throughput, cost-effective screening for larger-scale comparative drug studies. Generating data from more experiments in parallel the newest system in the portfolio enables in-plate replicates, controls and dose-response curves for enhanced data robustness, reproducibility and greater data confidence. 

Providing additional functionality, the Multi-organ System enables scientists to interconnect our liver-on-a-chip model with other organs, such as gut, lung or kidney. By mimicking how organs interact and communicate as part of a complex system, researchers benefit from a deeper human-specific mechanistic understanding of disease states and drug behaviour such as the ability to analyse target organ versus off-target effects, pharmacokinetics, bioavailability and biodistribution. This capability is facilitated by the Multi-chip Dual-organ plate (MPS-TL6) whose novel microfluidics enable recirculation of media from one culture compartment to the other to permit inter-organ crosstalk. When combined with PBPK mathematical modelling, in vitro data may be extrapolated to in vivo clinical predictions.

Through its ability to recreate human physiology in the lab, the PhysioMimix™ OOC range of microphysiological systems predict human responses to new therapeutic drug candidates. By supplementing data generated from entrenched 2D cell culture and animal studies, this system supports confident decision making across many drug discovery stages from target discovery right through to development. 
Its applications include:

• Disease modeling
• Drug safety toxicology
• ADME
• Pharmacology 
• Immune interactions
• Drug repurposing  

System features and benefits  

Despite the complex biology that they recreate, PhysioMimix™ OOC Systems are simple to install (< 1hr) and user-friendly to operate (< 1 min to program and start a run). To support users transitioning from 2D cell culture into 3D microtissues, a familiar open-well plate-based format has been incorporated into the design of consumables to ease adoption.   

First launched in 2018, this patented, proven technology offers the following features and benefits:  

• Versatile compatibility - organoids, spheroids, iPSCS, primary cells, immortalized cell lines tissue slices and commercial inserts  
• Multi-organ capability – link two or more tissue systems using microfluidics to reveal how multiple organs interact and respond to stimuli  
• Recirculated microfluidic flow - delivers biomechanical stimulus, oxygen and nutrients to cells retaining viability and phenotype over many weeks   
• Adjustable inter and intra “organ-specific” flow rates - to enhance physiological relevance  
• Open-well Multi-chip plates – To support users with an easy transition from 2D to 3D cell culture to develop their own models or follow our validated SOPs  
• PDMS-free consumable plates -ensures very low non-specific binding for true/ non-biased assessment of drug response   
• “Set-and-Run” Perfusion - automates long-term experiments for minimal user input over many weeks  
• Real-time monitoring - remove samples for analysis while experiments continue to run  
• Large sampling scale (up to 1 ml of media) – enables high content data generation, with multiple endpoint analysis and individual microtissues for deeper -omics and microscopic analysis  
• Unmatched OOC throughput - up to six OOC plates can be used to run multiple independent experiments simultaneously from one PhysioMimix™ OOC controller  
• Lab benchtop ready - portable and compact  Compatible with existing lab equipment - no additional purchases necessary